Indications and uses
Worms
Worms
QUASSIA AMARA HPUS 1X and higher
Worms
Condition listed above or as directed by the physician
Adults- Take 4 or 6 Pellets by mouth, three times daily or as suggested by physician. Children 2 years and older- take 1/2 the adult dose.
This product is to be used for self-limiting conditions
If symptoms do not improve in 4 days, or worsen, discontinue use and seek assistance of health professional
As with any drug, if you are preganant, or nursing a baby, seek professional advice before taking this product
Keep this and all medication out of reach of children
Sucrose
www.rxhomeo.com | 1.888.2796642 | info@rxhomeo.com
Rxhomeo, Inc 9415 Burnet Road, Suite 312, Austin, TX 78758
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 15631-0359-0 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-02e5-f424-e053-dadaa90a57ce | 91b83fce-f9e2-4fd7-936b-face25be0630 |
| 15631-0359-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-02e5-f424-e053-dadaa90a57ce | 91b83fce-f9e2-4fd7-936b-face25be0630 |
| 15631-0359-2 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-02e5-f424-e053-dadaa90a57ce | 91b83fce-f9e2-4fd7-936b-face25be0630 |
| 15631-0359-3 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-02e5-f424-e053-dadaa90a57ce | 91b83fce-f9e2-4fd7-936b-face25be0630 |
| 15631-0359-4 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-02e5-f424-e053-dadaa90a57ce | 91b83fce-f9e2-4fd7-936b-face25be0630 |
| 15631-0359-5 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-02e5-f424-e053-dadaa90a57ce | 91b83fce-f9e2-4fd7-936b-face25be0630 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 15631-0359-0 | QUASSIA AMARA | 100 in 1 PACKAGE | PELLET | 100 | 4 | |
| 15631-0359-1 | QUASSIA AMARA | 200 in 1 PACKAGE | PELLET | 200 | 4 | |
| 15631-0359-2 | QUASSIA AMARA | 400 in 1 PACKAGE | PELLET | 400 | 4 | |
| 15631-0359-3 | QUASSIA AMARA | 750 in 1 PACKAGE | PELLET | 750 | 4 | |
| 15631-0359-4 | QUASSIA AMARA | 2500 in 1 PACKAGE | PELLET | 2500 | 4 | |
| 15631-0359-5 | QUASSIA AMARA | 12500 in 1 PACKAGE | PELLET | 12500 | 4 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 15631-0359 | QUASSIA AMARA PELLET [RXHOMEO PRIVATE LIMITED D.B.A. RXHOMEO, INC] | 4 | Legacy NDC, 6 package rows | 20151113_91b83fce-f9e2-4fd7-936b-face25be0630.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| QUASSIA AMARA WOOD | ACTIVE INGREDIENT | S5249Q85HW | 4 | |
| QUASSIA AMARA WOOD | ACTIVE MOIETY | S5249Q85HW | 4 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 15631-0359 | 15631-0359-0, 15631-0359-1, 15631-0359-2, 15631-0359-3, 15631-0359-4, 15631-0359-5 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| QUASSIA AMARA WOOD | S5249Q85HW | ACTIB |
| SUCROSE | C151H8M554 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| e8381f81-21b4-4e07-8323-bdc599679bb7 | 91b83fce-f9e2-4fd7-936b-face25be0630 | 2015-11-12 | Warnings | e8381f81-21b4-4e07-8323-bdc599679bb7 91b83fce-f9e2-4fd7-936b-face25be0630 |
Adverse event summaries are temporarily unavailable. Other product information remains available.